Clinuvel and patient groups in the UK expect to find out this month whether a public hearing on NICE’s decision to recommend against funding the phototoxicity drug Scenesse (afamelanotide) has persuaded the health technology assessment institute to change its mind.
The hearing was held after the company and a number of patient and medical bodies lodged appeals against a decision...







